Get the Stockscreener App
26.20
4.13%
1.04
After Hours:
26.28
0.08
+0.31%
Travere Therapeutics Inc stock is traded at $26.20, with a volume of 1.55M.
It is up +4.13% in the last 24 hours and up +11.63% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$25.16
Open:
$25.17
24h Volume:
1.55M
Relative Volume:
0.79
Market Cap:
$2.34B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-12.84
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
+0.27%
1M Performance:
+11.63%
6M Performance:
+80.69%
1Y Performance:
+59.66%
1-Day Range:
$25.09
$26.36
1-Week Range:
$24.88
$27.20
52-Week Range:
$12.91
$28.69
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
26.20 | 2.24B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Can Travere Therapeutics Inc. stock outperform in 2025 bull marketWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Why Travere Therapeutics Inc. stock could outperform in 2025Market Risk Report & Daily Growth Stock Tips - newser.com
Backtesting results for Travere Therapeutics Inc. trading strategiesJuly 2025 Patterns & Consistent Profit Alerts - newser.com
How moving averages guide Travere Therapeutics Inc. tradingRecession Risk & Safe Capital Investment Plans - newser.com
Analyzing drawdowns of Travere Therapeutics Inc. with statistical tools2025 Market Outlook & Real-Time Market Trend Scan - newser.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 10, 2025 - BioSpace
Will Travere Therapeutics Inc. price bounce be sustainableQuarterly Investment Review & Fast Moving Trade Plans - newser.com
What moving averages say about Travere Therapeutics Inc.Quarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
Focal Segmental Glomerulosclerosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva Pharma - The Globe and Mail
How to recover losses in Travere Therapeutics Inc. stock2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Can Travere Therapeutics Sustain Its 48.9% Rally Amid Pipeline Progress in 2025? - Yahoo Finance
Can trapped investors hope for a rebound in Travere Therapeutics Inc.Market Performance Report & Technical Pattern Recognition Alerts - newser.com
What dividend safety score for Travere Therapeutics Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
What candlestick patterns are forming on Travere Therapeutics Inc.Market Activity Summary & Breakout Confirmation Alerts - newser.com
Will Travere Therapeutics Inc. stock deliver consistent dividendsMarket Activity Recap & Weekly Momentum Picks - newser.com
Real time breakdown of Travere Therapeutics Inc. stock performanceJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Travere therapeutics CFO sells $104,463 in stock - MSN
Building trade automation scripts for Travere Therapeutics Inc.Bond Market & Real-Time Market Sentiment Alerts - newser.com
Heatmap analysis for Travere Therapeutics Inc. and competitors2025 Volatility Report & Fast Entry and Exit Trade Plans - newser.com
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN
Published on: 2025-10-03 01:41:47 - newser.com
Why Travere Therapeutics Inc. stock remains on watchlists2025 Buyback Activity & Verified Short-Term Trading Plans - newser.com
Using data tools to time your Travere Therapeutics Inc. exit2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Travere Therapeutics stock rises on sNDA submission plans for FILSPARI - MSN
How to use a screener to detect Travere Therapeutics Inc. breakoutsGap Up & Risk Controlled Stock Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Trading Down 7.6%What's Next? - MarketBeat
Travere therapeutics CAO Calvin Sandra sells $17,520 in stock - MSN
Published on: 2025-09-29 13:53:58 - newser.com
Published on: 2025-09-29 12:50:11 - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Travere therapeutics CEO Eric M. Dube sells $273,455 in stock - MSN
Is GAIL India Limited One of the Top Picks for Growth Investors in YEARFlag and Pennant Patterns & Free Phenomenal Trading Returns - earlytimes.in
Published on: 2025-09-28 13:45:23 - earlytimes.in
Published on: 2025-09-28 02:30:57 - newser.com
Travere Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Double Digit Returns - earlytimes.in
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):